Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update

Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed against a strong run in Gilead Sciences’ shares, with the 90 day share price return of 20.67% and year to date gain of 28.32% lifting the stock to US$156.04. The 5 year total shareholder return of 187.39% points to sustained momentum rather than a short...